← Leaderboards
Maria Grazia Ferrari
Bioqual, Inc.
$1,216,423
Attributed
$1,216,423
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $765.3K · FY2022–23$1M$750K$500K$250K$0
'22
'23
Funding mix
By agency
NIH$1,216,423 · 1
By mechanism
N01$1,216,423 · 1
Top collaborators
No co-investigators on record.
Most similar at Bioqual, Inc.
Same institution · by research overlap
- Mark Lewis$23,081,773
- Deborah Weiss$695,753
- Hanne Andersen$3,809,803
- Richard P Bradbury$69,368
- Hanne Elyard$5,288,850
Others in their field
Other Rising Stars on “Virus Diseases”
- Gene Garrard Olinger · University Of Texas Med Br Galveston$23,000,000
- Kevin V Grimes · Stanford University$14,783,804
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Michael George Natchus · Emory University$10,548,554
- Anice Lowen · Emory University$10,193,979
- Joseph Fraser Glickman · Hackensack University Medical Center$8,363,749
Research focus
Virus DiseasesAdjuvantAgonistAids PreventionAids VaccinesAluminum SulfateBreedingClinical EfficacyEnv GlycoproteinsEvaluationEvaluation/TestingFlexibilityFormulationHiv-1Hiv VaccineHousingImmune ResponseImmunogenicityAdaptive Immune ResponseMaintenanceModalityMucosal Immune ResponsesNational Institute Of Allergy And Infectious DiseaseNonhuman Primate
Grant awards (2)
Evaluation of the Immunogenicity and Efficacy of HIV-1 Clade A BG505 SOSIP.664 Env Glycoprotein Trimer Vaccine Administered with TLR Agonist or Alum Adjuvants$451,088
N01 · FY2023 · AI · contact PI
Evaluation of the Immunogenicity and Efficacy of HIV-1 Clade A BG505 SOSIP.664 Env Glycoprotein Trimer Vaccine Administered with TLR Agonist or Alum Adjuvants$765,335
N01 · FY2022 · AI · contact PI